Protagenic Therapeutics, Inc.\new Professional Fees
Protagenic Therapeutics, Inc.\new (PTIX) reported Professional Fees of $284.54 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ProfessionalFees · last filed 2026-08-19
- Protagenic Therapeutics, Inc.\new professional fees for the quarter ending 2026-06-30 was $284.54K, a 81.51% increase year-over-year.
- Protagenic Therapeutics, Inc.\new professional fees for the quarter ending 2026-03-31 was $463.38K, a 88.70% increase year-over-year.
- Protagenic Therapeutics, Inc.\new professional fees for the quarter ending 2025-12-31 was $245.83K, a 62.24% increase year-over-year.
- Protagenic Therapeutics, Inc.\new professional fees for the quarter ending 2025-09-30 was $73.24K, a 56.70% decline year-over-year.
- Protagenic Therapeutics, Inc.\new professional fees for fiscal 2026 was $939.21K, a 40.69% increase from fiscal 2025.
- Protagenic Therapeutics, Inc.\new professional fees for fiscal 2025 was $667.58K.
| Period end | Professional Fees 3 month | Professional Fees 6 month | Professional Fees 9 month | Professional Fees 12 month |
|---|---|---|---|---|
| 2026-06-30 | $284.54K 10-Q · filed 2026-08-19 | $747.92K derived: sum of 2 quarters · filed 2026-08-19 | $993.75K derived: sum of 3 quarters · filed 2026-08-19 | $1.07M derived: sum of 4 quarters · filed 2026-08-19 |
| 2026-03-31 | $463.38K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-14 | $709.21K derived: sum of 2 quarters · filed 2026-08-14 | $782.45K derived: sum of 3 quarters · filed 2026-08-14 | $939.21K 10-K · filed 2026-08-14 |
| 2025-12-31 | $245.83K 10-Q · filed 2026-03-09 | $319.07K derived: sum of 2 quarters · filed 2026-03-09 | $475.83K 10-Q · filed 2026-03-09 | $721.39K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-09-30 | $73.24K 10-Q · filed 2025-11-26 | $230.00K 10-Q · filed 2025-11-26 | $475.57K derived: sum of 3 quarters · filed 2026-08-19 | $627.09K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-06-30 | $156.76K 10-Q · filed 2026-08-19 | $402.32K derived: sum of 2 quarters · filed 2026-08-19 | $553.84K derived: sum of 3 quarters · filed 2026-08-19 | $722.99K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-03-31 | $245.56K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-14 | $397.08K derived: sum of 2 quarters · filed 2026-08-14 | $566.23K derived: sum of 3 quarters · filed 2026-08-14 | $667.58K 10-K · filed 2026-08-14 |
| 2024-12-31 | $151.52K 10-Q · filed 2026-03-09 | $320.66K derived: sum of 2 quarters · filed 2026-03-09 | $422.02K 10-Q · filed 2026-03-09 | |
| 2024-09-30 | $169.14K 10-Q · filed 2025-11-26 | $270.50K 10-Q · filed 2025-11-26 | ||
| 2024-06-30 | $101.36K 10-QT · filed 2025-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |